Abstracts Archive - Page 1844 of 2607 - ACR Meeting Abstracts

Abstract Number: 2854 • 2015 ACR/ARHP Annual Meeting
Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Désirée van der Heijde¹, Maxime Dougados², Walter Maksymowych³, Gina Bergman⁴, Sean P. Curtis⁴, Anjela Tzontcheva⁴, George Philip⁴, Susan Huyck⁴ and Joachim Sieper⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Paris-Descartes University, Paris, France, ³University of Alberta, Edmonton, AB, Canada, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: The tolerability and efficacy of golimumab (GLM) as a treatment for nonradiographic axial spondyloarthritis (nr-axSpA) were recently investigated in a randomized, double-blind (DB), placebo…
Abstract Number: 2855 • 2015 ACR/ARHP Annual Meeting
Non-Response to Antitnf Treatment in Psoriatic Arthritis Can be Predicted By an Objective Automated Measurement of Fluorescence-Signal Intensities in Fluorescence-Optical Imaging Technique – the First Interims Analysis of the Xplore-Study
Michaela Koehm^1,2, Tanja Rossmanith³, Ulf Henkemeier⁴, Peer Aries⁵, Rieke Alten⁶, Hans-Eckhard Langer⁷, Harald Burkhardt^8,9 and Frank Behrens^1,9, ¹Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ³Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ⁴Centre of Innovative Diagnostics and Therapeutics Rheumatology/Immunology at Goethe-University, Frankfurt, Germany, ⁵Rheumatologie im Struenseehaus, Hamburg, Germany, ⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁷RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁸Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disorder. AntiTNF-therapy is initiated after failure of NSAID and DMARD-treatment. Up to 30-40% of the patients are…
Abstract Number: 2856 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylarthritis As Well As Peripheral Arthritis: Results from 2 Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Luis Puig², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Yin You⁵, Shu Li⁵, Michael Song⁵, Bruce Randazzo⁵, Proton Rahman⁶ and Iain. B. McInnes⁷, ¹University of California San Diego, La Jolla, CA, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Rheumatology, Memorial University of Newfoundland, St Johns, NF, Canada, ⁷Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate ustekinumab(UST) in a subgroup of psoriatic arthritis (PsA) pts with physician diagnosed spondylarthritis, as well as peripheral arthritis, from the PSUMMIT 1…
Abstract Number: 2857 • 2015 ACR/ARHP Annual Meeting
The 8-Year Retention Rate of the First TNF-Inhibitor in the Treatment of Spondyloarthropathies: Real-Life Data from Three Local Registries
Ennio Giulio Favalli¹, Andrea Becciolini¹, Martina Biggioggero², Enrico Fusaro³, Simone Parisi³, Alarico Ariani⁴, Daniele Santilli⁴, Antonio Marchesoni¹ and Pier Luigi Meroni², ¹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²University of Milan, Department of Clinical Sciences and Community Health, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, ³Città della salute e della Scienza, Turin, Italy, ⁴Department of Internal Medicine and Rheumatology, University of Parma, Parma, Italy
Background/Purpose: Long-term data on drug survival of TNF inhibitors (TNFi) in the treatment of spondyloarthropathies are still lacking. The aim of the study is to…
Abstract Number: 2858 • 2015 ACR/ARHP Annual Meeting
A Phosphodiesterase 4 Inhibitor for Psoriatic Arthritis: Systematic Review and Meta-Analysis
Ignacio-Alfredo Valerio-Morales¹, Maria A. Lopez-Olivo², Xin Pan³ and Maria E. Suarez-Almazor⁴, ¹Rheumatology, National Institute of Rehablitation, Mexico, Mexico, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Inhibition of phosphodiesterase (PDE) family enzymes is now recognized as target to develop new psoriatic arthritis (PsA) drugs. We conducted a systematic review to…
Abstract Number: 2859 • 2015 ACR/ARHP Annual Meeting
Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis
Atul A. Deodhar¹, Joachim Sieper², Owen Davies³, Tommi Nurminen⁴ and Philip J. Mease⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²University Hospital Charité, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Recent studies suggest that patients' (pts') body weight impacts response to anti-TNF treatment in pts with spondyloarthropathies1 including axial spondyloarthritis (axSpA).2 Here we investigate…
Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Arthur Kavanaugh¹, Dafna Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
Abstract Number: 2861 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns of Subcutaneous Biologic Agent Use Among Patients with Ankylosing Spondylitis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Background/Purpose: Ankylosing spondylitis (AS) is characterized by chronic debilitating inflammation of the spine and/or sacroiliac joints. Several biologic agents have been approved for the treatment…
Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting
Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa¹, Emilio Martín-Mola¹, Daniel Seoane-Mato³ and Juan D. Cañete⁴, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…
Abstract Number: 2863 • 2015 ACR/ARHP Annual Meeting
Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa³, Emilio Martín-Mola¹, Daniel Seoane-Mato⁴ and Juan D. Cañete⁵, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: In patients with axial spondyloarthritis (axSpA), anti-TNF therapy is successful for clinically improving signs and symptoms of the disease. However, there is no clear…
Abstract Number: 2864 • 2015 ACR/ARHP Annual Meeting
Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
Frank Zhang¹, Zoe Clancy² and Stan Li³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²33 Technology Drive, Celgene Corporation, Warren, NJ, ³Celgene Corporation, Warren, NJ
Background/Purpose: Studies have shown that patients with psoriatic arthritis (PsA) have significantly compromised physical health and quality of life, and negative effect on work productivity…
Abstract Number: 2865 • 2015 ACR/ARHP Annual Meeting
Methotrexate and Leflunomide Survival in Patients with Psoriatic Arthritis
Margarita Landi¹, Cecilia Zaffarana¹, Osvaldo Luis Cerda¹, Josefina Gallino Yanzi¹, Emilce Schneeberger¹, Ignacio Carrillo¹, María del Carmen Gonzalez Guzmán¹, Jose A Maldonado Cocco¹ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Disease Modifying Anti-Rheumatic Drugs (DMARDs) are frequently used in Psoriatic Arthritis (PsA), however there is limited data regarding their survival rates. This study attempts…
Abstract Number: 2866 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period
Proton Rahman¹, Michel Zummer², William G Bensen³, Isabelle Fortin⁴, Dalton Sholter⁵, Milton F. Baker⁶, Regan Arendse⁷, Eliofotisti Psaradellis⁸, Emmanouil Rampakakis⁹, Francois Nantel¹⁰, Allen J Lehman¹⁰, Cathy Tkaczyk¹¹, Karina Maslova¹⁰ and Brendan Osborne¹¹, ¹Medicine, Memorial University, St John's, NF, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶VIHA, Victoria, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy and tolerability of golimumab (GLM) in patients with psoriatic arthritis (PsA) has been demonstrated in several controlled clinical trials. Longitudinal observational studies…
Abstract Number: 2867 • 2015 ACR/ARHP Annual Meeting
Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Vibeke Strand¹, M. Elaine Husni², Zheng-Yi Zhou³, James Signorovitch³, Jenny Griffith⁴, Yichen Zhong³ and Arijit Ganguli⁴, ¹Stanford University, Palo Alto, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group, Inc., Boston, MA, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Progression of psoriatic arthritis (PsA) can lead to irreversible joint damage and functional impairment. TNF inhibitors (TNFi’s) have been shown to improve signs and…
Abstract Number: 2868 • 2015 ACR/ARHP Annual Meeting
Relative Efficacy of Adalimumab Versus Secukinumab in Active Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
Keith A. Betts¹, Manish Mittal², Avani Joshi², Jinlin Song¹ and Yanjun Bao², ¹Analysis Group, Inc., Boston, MA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: The phase 3 FUTURE 1 and FUTURE 2 trials demonstrated efficacy of secukinumab (SEC) for active psoriatic arthritis (PsA). However, there is limited data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].